GB Sciences One of Ten Companies Named in Important New Canadian Research Publication

GB Sciences mg Magazine

LAS VEGAS — GB Sciences, Inc. (OTCQB: GBLX) was named as one of the ten select cannabis companies in North America according to a study conducted by a leading investment banking firm in their June 20, 2018 Industry Report on Medical Cannabis. The report included deep research and analyst coverage on 31 public and 31 private cannabis companies from the US and Canada. GB Sciences was the only U.S. publicly traded company to make the list of ten companies.

The sixty-two target Companies were evaluated on the following criteria:
“Through our research, we have evaluated the clinical approach and fundamental technologies employed by a broad spectrum of companies participating in the clinical cannabis ecosystem. Here, we collect a group of 10 companies that we believe have the potential to capture the massive opportunities that lie in wait for those that focus on:


The consistent, large-scale production of high-quality cannabinoids;
The development of finely controlled, deeply studied cannabinoid drug formulations; and
The generation of gold standard clinical data supporting the registration of proprietary cannabinoid formulations to address specific clinical indications.”

Analyst Coverage for GB Sciences Inc. (GBLX-OTC):
“GB Sciences is a Nevada-based medical and recreational cannabis producer that is already generating revenue from its Las Vegas operations. What excites us most about GB, however, is its clinical discovery program. Chief Science Officer, Dr. Andrea Small-Howard, is using in silico data analysis to identify indications with well-established in vitro and in vivo model systems. By then applying molecular profiling of distinct cannabis strains, she is to undertake pharmaceutical-quality high-throughput screens of varying combinations of individual cannabinoids to identify profiles of up to 12 compounds in very specific ratios that can be applied to ameliorate specific disease indications. This rigorous, very pharmaceutical approach which does not hide behind the concept of the “entourage effect”, makes GB quite unique among U.S., and even Canadian cannabis producers.”

The ten select cannabis companies list:
Cansortium Holdings LLC (Private)
Avicanna Inc. (Private)
Tetra Bio-Pharma Inc. (TBP-T)
GB Sciences Inc. (GBLX-OTC)
Cardiol Therapeutics Inc. (Private)
Tilray (Private)
InMed Pharmaceutical Inc. (IN-T)
Technology: Ample Organics Inc. (Private) & Strainprint Technologies Ltd. (Private)
Village Farms International Inc. (VFF-T) / Emerald Health Therapeutics, Inc. (EMH-T)

GB Sciences has filed seven patents that cover over 100 separate and specific disease states. This fact, coupled with high profile research University partnerships on a global scale, singled the Company out as the only viable publicly traded U.S. candidate that fit the Top Ten evaluation criteria:

“As clearer signals of clinical cannabis’ efficacy in specific indications emerges from robust clinical evidence, the medical community—whose anathema is anecdote—will have the data- driven support it requires to adopt these drugs. With greater support from physicians comes greater buy-in from Pharma: soon, we may see clinical cannabis companies access markets much broader than those occupied by medical and adult use cannabis today, which, we suspect will be catalytic in spurring robust Pharma-cannabis transactions. For medical cannabis alone, we suspect that the well is much, much deeper than what today’s companies are drawing from at present.”
In addition to their robust IP portfolio, GB has solved a conundrum the Company terms as the Big Green Riddle (LINK TO THE DECK), which is the consistent, large-scale production of high-quality cannabinoids for medical formulations.

As Company Chairman and CEO John Poss explained, “The original vision for this company was to create an innovative drug development pipeline that put efficacious drugs in the hands of patients. All company endeavors revolve around this basic tenet. Even our adult use division is dedicated to producing the same trusted quality, purity and consistency in each and every one of our recreational products,” he continued, “To GB Sciences, all cannabis consumers are patients of one sort or another. And they all deserve the same trusted raw ingredients and high product standards. Our products are based on sound scientific principles and grounded in human service… and we’re proud of that.”